Author:
Thomas Robert,Oliveira Antonio Anax F.,Ponting David J.,Thresher Andrew
Subject
Toxicology,General Medicine
Reference7 articles.
1. Maximizing use of existing carcinogenicity data to support acceptable intake levels for mutagenic impurities in pharmaceuticals: Learnings from N-nitrosamine case studies;Felter;Regulatory Toxicology and Pharmacology,2023
2. A carcinogenic potency database of the standardized results of animal bioassays;Gold;Environ. Health Perspect.,1984
3. Assessment and control of dna reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk M7;Guideline,2014
4. The TD50: a proposed general convention for the numerical description of the carcinogenic potency of chemicals in chronic-exposure animal experiments;Peto;Environ. Health Perspect.,1984